Taxol (Breast Cancer) Analysis and Forecasts to 2020


#28309

44pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Taxol (Breast Cancer) Analysis and Forecasts to 2020 provides Taxol sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Taxol including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Taxol including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Taxol in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Report Guidance 7


3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 9
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 13


4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15


5 Predictive Biomarker in the Treatment of Breast Cancer 18


6 Treatment Options of Breast Cancer 20
6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 28


7 Taxol 30
7.1 Introduction 30
7.2 Mechanism of Action 30
7.3 Clinical Studies 30
7.3.1 Adjuvant Therapy 30
7.3.2 After Failure of Initial Chemotherapy 30
7.4 Approval History of Taxol 31
7.5 Factors Affecting Sales 31
7.5.1 Approval of Avastin in Combination with Taxol 31
7.5.2 Better Efficacy of Competing Drugs 31
7.5.3 Emergence of Targeted Therapies 31
7.6 Drug Risk Benefit Score 32
7.6.1 Efficacy 32
7.6.2 Safety 32
7.6.3 Compliance 32
7.6.4 Dosing Convenience 32
7.7 Intensity of Competition 32
7.8 Sales forecast 33
7.8.1 Target patient Pool of Taxol 33
7.8.2 Dosing 33
7.8.3 Market Penetration 34
7.8.4 Annual Cost of Therapy 34
7.8.5 Sales Projection of Taxol 34


8 Appendix 40
8.1 Market Definitions 40
8.2 Abbreviations 40
8.3 Research Methodology 40
8.3.1 Coverage 40
8.3.2 Secondary Research 41
8.3.3 Forecasting 41
8.3.4 Number of Patients Approved to take the Drug 41
8.3.5 Net Penetration of Drug 41
8.3.6 Net Annual Dosing 43
8.3.7 Annual Cost of Therapy 43
8.3.8 Primary Research 43
8.3.9 Expert Panels 43
8.4 Contact Us 44
8.5 Disclaimer 44
8.6 Sources 44


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 13
Table 4: Results of Phase III Trial of Taxol for Breast Cancer After Failure of Initial Chemotherapy 31
Table 5: Approval of Taxol 31
Table 6: Drug Risk Benefit Score of Taxol 32
Table 7: Annual Cost of Therapy of Taxol 34
Table 8: Taxol, Breast Cancer, Global, Sales Estimates ($m), 20022009 35
Table 9: Taxol, Breast Cancer, Global, Sales Forecasts ($m), 20102020 35
Table 10: Taxol, Breast Cancer, the US, Sales Estimates ($m), 20022009 36
Table 11: Taxol, Breast Cancer, the US, Sales Forecasts ($m), 20102020 36
Table 12: Taxol, Breast Cancer, EU, Sales Estimates ($m), 20022009 37
Table 13: Taxol, Breast Cancer, EU, Sales Forecasts ($m), 20102020 37
Table 14: Taxol, Breast Cancer, Japan, Sales Estimates ($m), 20022009 38
Table 15: Taxol, Breast Cancer, Japan, Sales Forecasts ($m), 20102020 38


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top 10 Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 25
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 28
Figure 33: Drug Model Diagram of Taxol in The US, EU and Japan 33
Figure 34: Taxol, Breast Cancer, Global, Sales Estimates ($m), 20022020 35
Figure 35: Taxol, Breast Cancer, the US, Sales Estimates ($m), 20022020 36
Figure 36: Taxol, Breast Cancer, EU, Sales Estimates ($m), 20022020 37
Figure 37: Taxol, Breast Cancer, Japan, Sales Estimates ($m), 2002-2020 38
Figure 38: Taxol, Breast Cancer, Global, Sales Distribution, 2010 39
Figure 39: Drug Model Diagram 42
Figure 40: Patients Approved to take the Drug 43